Elixinol Wellness (AU:EXL)
ASX:EXL
Top Page
Elixinol Wellness
(Sydney:EXL)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:ReiteratedDate:03/02/26
The score is held back primarily by weak financial performance (ongoing losses and negative cash flow, plus a weaker 2025 balance sheet) and bearish technicals (price below key moving averages and negative MACD). This is partially offset by an improved operating narrative from the earnings call, highlighting structural cost reductions and Q4 profitability/cash-flow progress, but execution and regulatory risks remain.
Positive Factors
Shift to higher‑margin revenue mix
A sustained reweighting to e-commerce (21%→38%) and reduction of low‑margin bulk improves gross margin potential and revenue stickiness. Higher D2C mix should raise lifetime value, increase pricing control and predictability, supporting durable cash generation if channel momentum continues.
Negative Factors
Persistent negative operating and free cash flow
Ongoing annual cash burn, including ~-A$3.2M OCF in 2025, erodes equity and forces reliance on external capital. Persistent negative cash flow constrains capex, marketing investment and M&A execution, and makes the company vulnerable to funding shocks if revenue or margin improvements stall.
Read all positive and negative factors
Positive Factors
Negative Factors
Shift to higher‑margin revenue mix
A sustained reweighting to e-commerce (21%→38%) and reduction of low‑margin bulk improves gross margin potential and revenue stickiness. Higher D2C mix should raise lifetime value, increase pricing control and predictability, supporting durable cash generation if channel momentum continues.
Read all positive factors
Elixinol Wellness (EXL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.90M
Dividend YieldN/A
Average Volume (3M)554.74K
Price to Earnings (P/E)―
Beta (1Y)-0.42
Revenue Growth36.60%
EPS Growth85.28%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding413,987,730
10 Day Avg. Volume558,811
30 Day Avg. Volume554,744
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.15
P/FCF Ratio-0.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Elixinol Wellness Business Overview & Revenue Model
Company Description
Elixinol Wellness Limited, through its subsidiaries, manufactures and distributes hemp derived nutraceuticals, cosmetics, and food products under the Elixinol and Hemp Foods Australia brands in the Americas, Europe, and Australia. It offers hemp d...
How the Company Makes Money
Elixinol Wellness generates revenue primarily through the sale of its hemp-derived CBD products, which are marketed to both retail consumers and wholesale clients. The company's revenue model includes direct-to-consumer sales via their online plat...
Elixinol Wellness Earnings Call Summary
Earnings Call Date:Feb 12, 2026
(Q4-2025)
| Next Earnings Date:Aug 27, 2026
Earnings Call Sentiment Positive
The call communicated meaningful operational progress: a clear shift to higher-margin channels (e-commerce up to 38%), significant cost structure reduction (~30% in Q4 vs prior year), Q4 profitability and positive operating cash flow, strong D2C momentum (Healthy Chef e-commerce +42% YoY) and product innovation poised to capture market trends. However, challenges remain including modest full-year revenue growth (3.6% YoY), a small absolute revenue base (~$15.5M), supermarket channel pressures for niche SKUs, and regulatory uncertainty in the U.S. CBD business. On balance, the operational improvements and trajectory toward sustainable profitability outweigh the outstanding strategic and market risks, but execution and regulatory clarity will be important near-term drivers.Positive Updates
Q4 Revenue Growth and Strong Exit Run-Rate
Q4 FY25 revenue of $4.1M, up 9.5% quarter-on-quarter, delivering a strong exit run-rate into FY26 and demonstrating seasonal rebound in the business.
Negative Updates
Modest Full-Year Top-Line Growth
FY25 revenue growth was modest at 3.6% year-over-year ($15.5M), indicating limited top-line expansion despite improvements in mix and margins.
Read all updates
Q4-2025 Updates
Positive
Negative
Q4 Revenue Growth and Strong Exit Run-Rate
Q4 FY25 revenue of $4.1M, up 9.5% quarter-on-quarter, delivering a strong exit run-rate into FY26 and demonstrating seasonal rebound in the business.
Read all positive updates
Company Guidance
Management guided FY26 around four pillars — operational momentum, cost efficiency, building a growth foundation and targeted M&A — with the aim of maintaining a structurally lower OpEx run‑rate after cutting the operating cost base by ~30% in Q4 vs Q4 FY24 and delivering Q4 positive EBITDA (slightly better than break‑even) and positive underlying operating cash flow; they completed a two‑tranche $2.5m capital raise and will review capital management at the May AGM. The company will prioritize higher‑margin D2C and e‑commerce (e‑commerce grew from 21% to 38% of revenue in 2025; Healthy Chef e‑commerce +42% YoY in Q4) while reducing low‑margin bulk (from 24% to 14%), leveraging FY25 revenue of $15.5m and a Q4 exit run‑rate of $4.1m (quarterly revenue ranged ~$3–4m) with contracted hemp volumes up for 2026. Management also signalled near‑term actions — pursuing value‑accretive acquisitions, keeping U.S. CBD options open pending regulatory clarity in 2–3 months, and driving product launches (Healthy Chef Metabolic Burn and protein water, plus Mt Elephant NPD into Coles in May) to capture large market opportunities (Australia wellness ~$160bn today to >$300bn by 2033 at ~7% growth, functional foods ~$10.5bn, protein market to $1.1bn by 2034) and narrow the current valuation gap (~0.3x revenue vs peers 1–1.5x).Elixinol Wellness Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.50M | 14.96M | 8.27M | 7.05M | 9.34M |
| Gross Profit | 752.00K | 5.36M | -1.80M | -3.27M | -6.25M |
| EBITDA | -4.11M | -4.01M | -6.81M | -9.28M | -15.51M |
| Net Income | -5.50M | -1.72M | -7.51M | -10.57M | -17.02M |
Balance Sheet | |||||
| Total Assets | 15.96M | 18.45M | 11.71M | 13.48M | 25.33M |
| Cash, Cash Equivalents and Short-Term Investments | 1.41M | 1.08M | 708.00K | 2.86M | 12.65M |
| Total Debt | 3.95M | 1.94M | 1.26M | 1.83M | 2.71M |
| Total Liabilities | 8.51M | 8.42M | 5.25M | 4.33M | 6.25M |
| Stockholders Equity | 7.45M | 10.03M | 6.46M | 9.16M | 19.08M |
Cash Flow | |||||
| Free Cash Flow | -3.28M | -3.53M | -2.77M | -8.16M | -14.36M |
| Operating Cash Flow | -3.21M | -3.47M | -2.76M | -8.15M | -14.07M |
| Investing Cash Flow | -216.00K | -66.00K | -1.04M | -869.00K | 172.00K |
| Financing Cash Flow | 3.65M | 3.92M | 1.61M | -757.00K | -1.16M |
Elixinol Wellness Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Negative
44.76
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EXL, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.76 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EXL.
Elixinol Wellness Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | AU$136.69M | 13.85 | 19.15% | 4.33% | 8.46% | -1.95% | |
57 Neutral | AU$25.18M | -12.06 | 7.64% | 3.28% | 0.13% | -12.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$2.90M | -0.42 | -76.30% | ― | 36.60% | 85.28% | |
43 Neutral | AU$19.73M | -2.87 | 4388.00% | ― | -47.30% | 82.53% | |
39 Underperform | AU$9.58M | 0.07 | 93.89% | ― | -26.49% | 61.72% |
* Healthcare Sector Average
AU:EXL
Elixinol Wellness
0.01
-0.02
-67.74%
AU:CAN
Cann Group
0.01
-0.02
-62.96%
AU:VLS
Vita Life Sciences Limited
2.51
0.76
43.43%
AU:LGP
Little Green Pharma Ltd.
0.10
-0.02
-19.17%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-22.73%
AU:VIT
Cronos Australia Ltd.
0.04
-0.03
-42.42%
Elixinol Wellness Corporate Events
Elixinol Wellness Builds Vertically Integrated Nutrition and Wellness Platform
Feb 27, 2026
Elixinol Wellness is positioning itself as a sustainable nutrition and wellness player with vertically integrated operations in Australia and the U.S., spanning production, manufacturing and distribution. Its brands, including The Healthy Chef, He...
Elixinol Wellness files updated corporate governance statement and Appendix 4G
Feb 27, 2026
Elixinol Wellness has lodged its latest corporate governance statement for the financial year ended 31 December 2025, confirming that the statement is current as of 27 February 2026 and has been approved by the board. The company has opted to publ...
Elixinol Wellness Revenue Edges Higher as Losses Deepen and Net Tangible Assets Turn Negative
Feb 27, 2026
Elixinol Wellness Limited reported a 3.6% rise in revenue to $15.5 million for the year ended 31 December 2025, but its net loss attributable to owners widened sharply to $5.5 million, a 219.4% increase from the prior year. Basic and diluted loss ...
Elixinol Wellness Sets Investor Webinar to Discuss Q4 FY25 Results and Outlook
Feb 10, 2026
Elixinol Wellness Ltd has scheduled an investor webinar for 10:00am AEDT on Thursday 12 February 2026, where management will present the company’s Q4 FY25 results and outlook before taking questions. The session signals the company’s e...
Elixinol Wellness Lifts Revenue, Cuts Costs and Turns Cash Flow Positive in Q4 FY25
Jan 29, 2026
Elixinol Wellness reported December quarter FY25 revenue of $4.1 million, up 9.5% quarter-on-quarter, contributing to full-year FY25 revenue of $15.5 million, a 3.6% increase year-on-year driven by portfolio rationalisation and a focus on higher-m...
Elixinol Wellness Announces Expiry of 58,220 Performance Rights
Jan 15, 2026
Elixinol Wellness Limited has reported that 58,220 performance rights on issue under ASX code EXLAC have lapsed unexercised following their expiry on 15 January 2026. The expiry slightly reduces the company’s pool of potential equity-based i...
Elixinol Director Gavin Evans Increases Indirect Shareholding via On‑Market Trades
Jan 1, 2026
Elixinol Wellness Limited has disclosed a change in the relevant interests of director Gavin Evans, in line with ASX listing rule 3.19A.2 reporting requirements. The director, via a superannuation fund account, acquired 397,010 fully paid ordinary...
Elixinol Wellness Appoints RSM Australia as New Auditor After BDO Resigns
Dec 19, 2025
Elixinol Wellness has announced a change of auditor following the Australian corporate regulator’s consent to the resignation of BDO Audit, which stepped down effective 18 December 2025 without identifying any reportable matters linked to it...
Elixinol Wellness Revises Terms for The Healthy Chef to Strengthen Market Focus
Dec 18, 2025
Elixinol Wellness has revised the acquisition terms for its subsidiary, The Healthy Chef, following the withdrawal of a major US distribution partner, resulting in reduced liabilities and enhanced liquidity by A$1 million. With a focus on the Aust...
Elixinol Wellness Reveals Top Option Holders
Dec 9, 2025
Elixinol Wellness Limited has released a report detailing the top holders of its listed options, which are priced at $0.02 and have a two-year expiration from the issue date. The report highlights that 10 Bolivianos Pty Ltd holds the largest share...
Elixinol Wellness Applies for Quotation of New Securities
Dec 9, 2025
Elixinol Wellness Limited has announced a new application for the quotation of securities on the ASX, with a total of 218,796,310 options expiring on October 23, 2027, set to be issued on November 25, 2025. This move is likely to impact the compan...
Elixinol Wellness Appoints New Director with Significant Stake
Dec 9, 2025
Elixinol Wellness Limited has announced the appointment of Gavin Evans as a director, effective December 2, 2025. Evans holds 50,000,000 unlisted options and 7,407,407 fully paid ordinary shares, indicating a significant stake in the company. This...
Elixinol Wellness Appoints Gavin Evans as New Chair Amid Strategic Shift
Dec 2, 2025
Elixinol Wellness has announced the resignation of David Fenlon as Chair of the Board, with Gavin Evans stepping in as the new Independent Non-Executive Chair. Evans, who has a strong background in building profitable wellness businesses, has been...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.